WHO moves to widen access to generic Sovaldi in dozens of countries
After India, I-MAK files legal challenge against Gilead’s hepatitis C drug sofosbuvir in China
Gilead faces fresh patent challenges over hepatitis C drugs in India
Sovaldi patent ruling not a game-changer, yet NGO, drugmaker both weigh appeals to partial ruling.
Partial Revocation Of EPO Patent On Sofosbuvir, Key For Hepatitis C
European regulator amends some Gilead hep C patent claims
China Declined The Patent Application Of Gilead Sciences, Inc.’s Sovaldi Prodrug
China rejects patent linked to Gilead hepatitis C drug
Gilead Patent for its Sovaldi Hep C Drug is Rejected by Chinese Authorities
Activists Challenge Gilead’s Patents on Costly Hepatitis C Drug Sovaldi